# Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

- Source: PR Newswire M&A
- Published: 2026-11-02T06:47:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/fresenius-and-wuxi-biologics-enter-exclusive-development-agreement-to-expand-biosimilars-pipeline-302926065.html
- Canonical: https://groundlevelnews.com/story/fresenius-and-wuxi-biologics-enter-exclusive-development-agreement-to--16d237/

Exclusive option rights for up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius' portfolio from 29 marketed and pipeline molecules today to up to 66 in the next decade, addressing more than €370 billion in originator sales; the largest development...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._